Metformin Use in Patients With Diabetes Mellitus and Heart Failure: Friend or Foe?

Journal of Cardiac Failure

Volumn 16, Issue 3, 2010, Pages 207-210

  Giamouzis, Gregory ^a   Triposkiadis, Filippos ^a   Butler, Javed ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

COMORBIDITY; DIABETES MELLITUS; DRUG MECHANISM; DRUG USE; EDITORIAL; HEART FAILURE; HUMAN; LACTIC ACIDOSIS; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77549083299     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.12.007     Document Type: Editorial

References (39)

1. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., and Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27 (2004) 1879-1884
2. Kalogeropoulos A., Georgiopoulou V., Harris T.B., Kritchevsky S.B., Bauer D.C., Smith A.L., et al. Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the health, aging, and body composition study. J Card Fail 15 (2009) 593-599
3. Kostis J.B., and Sanders M. The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens 18 (2005) 731-737
4. Solang L., Malmberg K., and Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 20 (1999) 789-795
5. Adams Jr. K.F., Fonarow G.C., Emerman C.L., LeJemtel T.H., Costanzo M.R., Abraham W.T., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
6. De Groote P., Lamblin N., Mouquet F., Plichon D., McFadden E., Van Belle E., et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25 (2004) 656-662
7. Dries D.L., Sweitzer N.K., Drazner M.H., Stevenson L.W., and Gersh B.J. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 38 (2001) 421-428
8. Standards of Medical Care in Diabetes-2009. Diabetes Care 32 Suppl 1 (2009) S13-S61
9. Aguilar D., Bozkurt B., Ramasubbu K., and Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 54 (2009) 422-428
10. Weinrauch L.A., and Lewis E.F. Aiming for the best control of glycemia in patients with heart failure and type 2 diabetes the "sweet spot". J Am Coll Cardiol 54 (2009) 429-431
11. Giamouzis G., and Butler J. Relationship between heart failure and lipids: the paradigm continues to evolve. J Card Fail 13 (2007) 254-258
12. Johnson J.A., Majumdar S.R., Simpson S.H., and Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25 (2002) 2244-2248
13. Johnson J.A., Simpson S.H., Toth E.L., and Majumdar S.R. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabetes Med 22 (2005) 497-502
14. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
15. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
16. Nichols G.A., Koro C.E., Gullion C.M., Ephross S.A., and Brown J.B. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 21 (2005) 51-57
17. DeFronzo R.A., and Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333 (1995) 541-549
18. Stang M., Wysowski D.K., and Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 22 (1999) 925-927
19. Misbin R.I., Green L., Stadel B.V., Gueriguian J.L., Gubbi A., and Fleming G.A. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338 (1998) 265-266
20. Aguilar C., Reza A., Garcia J.E., and Rull J.A. Biguanide related lactic acidosis: incidence and risk factors. Arch Med Res 23 (1992) 19-24
21. Brown J.B., Pedula K., Barzilay J., Herson M.K., and Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 21 (1998) 1659-1663
22. Bailey C.J., and Turner R.C. Metformin. N Engl J Med 334 (1996) 574-579
23. Aldasouqi S.A., and Duick D.S. Safety issues on metformin use. Diabetes Care 26 (2003) 3356-3357
24. Salpeter S., Greyber E., Pasternak G., and Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 1 (2006) CD002967
25. Inzucchi S.E., Masoudi F.A., Wang Y., Kosiborod M., Foody J.M., Setaro J.F., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28 (2005) 1680-1689
26. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., and Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111 (2005) 583-590
27. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., and Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28 (2005) 2345-2351
28. Eurich D.T., McAlister F.A., Blackburn D.F., Majumdar S.R., Tsuyuki R.T., Varney J., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335 (2007) 497
29. Klip A., and Leiter L.A. Cellular mechanism of action of metformin. Diabetes Care 13 (1990) 696-704
30. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001) 1167-1174
31. Xie Z., Dong Y., Scholz R., Neumann D., and Zou M.H. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 117 (2008) 952-962
32. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51 (2002) 2074-2081
33. Chan A.Y., Soltys C.L., Young M.E., Proud C.G., and Dyck J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279 (2004) 32771-32779
34. Russell III R.R., Li J., Coven D.L., Pypaert M., Zechner C., Palmeri M., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114 (2004) 495-503
35. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11 (2005) 1096-1103
36. Davis B.J., Xie Z., Viollet B., and Zou M.H. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55 (2006) 496-505
37. Marfella R., Acampora R., Verrazzo G., Ziccardi P., De Rosa N., Giunta R., et al. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care 19 (1996) 934-939
38. Sasaki H., Asanuma H., Fujita M., Takahama H., Wakeno M., Ito S., et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 119 (2009) 2568-2577
39. Shah D.D., Fonarow G.C., and Horwich T.B. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 16 (2010) XXX-XXX